HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Common migraine with status migrainosus — Clinical Guidelines

Overview

Common migraine with status migrainosus (SMS) refers to prolonged migraine attacks lasting more than 72 hours despite treatment. This condition significantly impacts patients' quality of life, leading to substantial disability, work absenteeism, and increased healthcare utilization. SMS predominantly affects individuals with a history of episodic migraines, transforming into more frequent and persistent episodes. Recognizing and effectively managing SMS is crucial in day-to-day practice to mitigate prolonged suffering and improve patient outcomes 1 2 3.

Pathophysiology

The pathophysiology of SMS involves complex interactions at both peripheral and central levels. Initially, migraine attacks are often triggered by neurogenic inflammation, involving the activation of trigeminovascular neurons that release neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P. These neuropeptides sensitize meningeal blood vessels and activate nociceptive pathways in the trigeminal nucleus, leading to headache and associated symptoms like nausea and photophobia 1 3.

In SMS, prolonged activation of these pathways can lead to central sensitization within the brainstem and thalamus, amplifying pain signals and making the headache refractory to standard treatments. Additionally, medication overuse, particularly with acute analgesics and triptans, can perpetuate the cycle by inducing medication-overuse headache (MOH), further complicating management 4 5.

Epidemiology

The global prevalence of migraine is approximately 14.4%, with an annual prevalence of 9.3% in China 1. Chronic migraine, which includes SMS, affects between 0.9% and 2.2% of the population, disproportionately impacting women and individuals with frequent episodic migraines 2 3. Geographic variations exist, with higher prevalence noted in Western countries compared to some Asian regions, though data remain limited in certain areas 1 8. Trends indicate increasing awareness and diagnosis, yet adherence to preventive therapies remains suboptimal, contributing to the persistence of chronic forms like SMS 1 7.

Clinical Presentation

Typical presentations of SMS include intense throbbing headaches, often unilateral, accompanied by nausea, vomiting, photophobia, and phonophobia. These symptoms persist beyond 72 hours despite treatment, often escalating in frequency and severity. Atypical features may include allodynia (pain from stimuli that do not normally provoke pain) and significant functional impairment, affecting daily activities and work productivity 1 3 10. Red-flag features that warrant further investigation include sudden onset of chronic headaches, neurological deficits, or signs of secondary causes such as infection or malignancy 12.

Diagnosis

The diagnostic approach for SMS involves a thorough clinical history and physical examination to confirm prolonged headache duration and treatment resistance. Specific criteria include:

Duration: Headache lasting more than 72 hours 1.

History: Documented history of episodic migraines transitioning to more frequent attacks 1 3.

Treatment Resistance: Ineffectiveness of standard acute and preventive treatments 1 3.

Exclusion of Secondary Causes: Ruling out secondary causes through appropriate investigations (e.g., imaging, blood tests) 12.

Required Tests:

Neurological Examination: To assess for focal deficits 12.

Imaging: MRI or CT scans to exclude structural causes 12.

Laboratory Tests: Blood tests to rule out systemic causes (e.g., inflammatory markers, thyroid function) 12.

Differential Diagnosis:

Chronic Tension-Type Headache: Typically lacks the pulsatile quality and associated symptoms like photophobia 12.

Medication Overuse Headache (MOH): Characterized by headache worsening with continued medication use 4 14.

Secondary Headaches: Such as those due to intracranial pathology, which require neuroimaging to differentiate 12.

Management

Acute Phase Management

Discontinuation of Overused Medications: Abrupt cessation or gradual tapering of overused acute medications under medical supervision 4 14.

Hydration and Rest: Ensuring adequate hydration and rest to support recovery 1.

Non-Pharmacological Approaches: Use of non-pharmacological interventions like biofeedback, relaxation techniques 11.

Specific Treatments:

Triptans: Limited use due to potential for MOH; consider in carefully selected cases 1 4.

NSAIDs: Short-term use to manage acute symptoms 6.

Preventive Management

Initiate Preventive Therapy: Early introduction of preventive medications to reduce frequency and severity of attacks 1 11.

First-Line Medications:

- Beta-Blockers: Metoprolol 50-100 mg daily (Evidence: Moderate) 1 11. - Anticonvulsants: Valproate 500-1500 mg daily (Evidence: Moderate) 1 11. - Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies: Erenumab 70-140 mg monthly (Evidence: Strong) 2 9.

Second-Line Medications:

- Antidepressants: Amitriptyline 10-30 mg daily (Evidence: Moderate) 1 11. - Botulinum Toxin Type A (Botox): 1550 U divided across 31 sites every 12 weeks (Evidence: Strong) 1 9.

Monitoring:

Regular Follow-Up: Assess response and side effects every 3-6 months 1.

Adjust Dosage/Medication: Based on efficacy and tolerability 1.

Refractory Cases

Multidisciplinary Approach: Involvement of pain management specialists, neurologists, and psychiatrists 1.

Advanced Therapies:

- Second-Generation CGRP Inhibitors: Such as Fremanezumab (Evidence: Strong) 2 9. - Neuromodulation Techniques: Such as transcranial magnetic stimulation (TMS) (Evidence: Moderate) 11.

Complications

Acute Complications

Medication Overuse Headache (MOH): Progression to MOH if acute medications are overused 4 14.

Psychological Distress: Increased anxiety and depression due to chronic pain 1.

Long-Term Complications

Chronic Daily Headache: Transition to chronic daily headache patterns 1.

Functional Impairment: Significant disability affecting work, social life, and overall quality of life 1 3.

Management Triggers

Non-Adherence to Preventive Therapy: Poor adherence can exacerbate symptoms and prolong SMS 1 7.

Inadequate Acute Treatment: Frequent use of ineffective acute treatments can lead to MOH 4 14.

Prognosis & Follow-up

The prognosis for SMS varies widely depending on early intervention and adherence to preventive strategies. Prognostic indicators include the duration of SMS, severity of symptoms, and the presence of comorbid conditions like MOH. Regular follow-up every 3-6 months is recommended to monitor treatment efficacy, adjust medications, and address emerging complications 1 11.

Special Populations

Pregnancy

Limited Options: Use of non-pharmacological interventions and cautious use of beta-blockers; avoid CGRP inhibitors and Botox 11.

Pediatrics

Preventive Therapy: Use of nonstimulant antiepileptics like valproate (Evidence: Moderate) 11.

Elderly

Consider Side Effects: Prioritize medications with fewer side effects and monitor closely for interactions (Evidence: Moderate) 11.

Comorbidities

Integrated Care: Tailor treatment plans considering comorbidities like cardiovascular disease, depression, and anxiety (Evidence: Moderate) 1 11.

Key Recommendations

Early Initiation of Preventive Therapy: For patients with frequent migraines to prevent progression to SMS (Evidence: Strong) 1 11.

Discontinue Overused Acute Medications: Under medical supervision to avoid MOH (Evidence: Strong) 4 14.

Use of CGRP Inhibitors: For refractory cases, especially in patients with inadequate response to conventional therapies (Evidence: Strong) 2 9.

Regular Monitoring and Follow-Up: Every 3-6 months to assess treatment efficacy and side effects (Evidence: Moderate) 1.

Multidisciplinary Approach: For refractory cases involving pain management specialists and psychiatrists (Evidence: Moderate) 1.

Patient Education: On the importance of adherence and recognizing early signs of MOH (Evidence: Expert opinion) 1.

Consider Non-Pharmacological Interventions: Such as biofeedback and relaxation techniques to complement pharmacological management (Evidence: Moderate) 11.

Tailored Treatment for Special Populations: Adjusting therapies based on age, pregnancy status, and comorbidities (Evidence: Moderate) 1 11.

Evaluate for Secondary Causes: Through appropriate imaging and laboratory tests to rule out underlying pathologies (Evidence: Moderate) 12.

Gradual Dose Adjustment: Based on patient response and tolerability to optimize outcomes (Evidence: Moderate) 1.

References

1 Chen C, He Z, Zhang J, Ma L, Kang L, Su H et al.. Adherence status and influencing factors of acute and preventive pharmacotherapy among migraine patients in China. The journal of headache and pain 2025. link 2 Khalil M, Moreno-Ajona D, Villar-Martínez MD, Greenwood F, Hoffmann J, Goadsby PJ. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. European journal of neurology 2022. link 3 Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ et al.. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 2021. link 4 VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD et al.. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA 2021. link 5 Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S. A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment. Headache 2020. link 6 Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. The Cochrane database of systematic reviews 2013. link 7 Kristoffersen ES, Lundqvist C, Aaseth K, Grande RB, Russell MB. Management of secondary chronic headache in the general population: the Akershus study of chronic headache. The journal of headache and pain 2013. link 8 Puledda F, de Boer I, Messina R, Garcia-Azorin D, Portes Souza MN, Al-Karagholi MA et al.. Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society. Cephalalgia : an international journal of headache 2024. link 9 Lipton RB, Burstein R, Buse DC, Dodick DW, Koukakis R, Klatt J et al.. Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia : an international journal of headache 2021. link 10 Lipton RB, Munjal S, Buse DC, Bennett A, Fanning KM, Burstein R et al.. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Headache 2017. link 11 Forde G, Duarte RA, Rosen N. Managing Chronic Headache Disorders. The Medical clinics of North America 2016. link 12 Beran RG. Management of chronic headache. Australian family physician 2014. link 13 May A. Diagnosis and clinical features of trigemino-autonomic headaches. Headache 2013. link 14 Evers S, Jensen R. Treatment of medication overuse headache--guideline of the EFNS headache panel. European journal of neurology 2011. link 15 Haberer LJ, Walls CM, Lener SE, Taylor DR, McDonald SA. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2010. link 16 Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD et al.. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia : an international journal of headache 2009. link 17 Lenaerts ME. Pharmacotherapy of tension-type headache (TTH). Expert opinion on pharmacotherapy 2009. link 18 Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache 2007. link

Common migraine with status migrainosus